26. Pharmacokinetics/Pharmacodynamics Expert Meeting
Shaping the future - Quo vadis PK/PD?
From March 14 till March 16, 2024
Event location: Isny (Link)
Presentations and associated discussions will focus on the following topics:
- How do PK/PD principles support new modalities? – Contributions and challenges
- Beyond traditional models: New approaches with high impact on PK/PD
- Advancements in classical topics: Recent approaches in pediatrics
We look forward to seeing you in Isny in March 2024.
Kind regards,
Dr. Alexander Staab
on behalf of the Organizing Committee
Dr. Sybille Baumann
President AGAH e. V.
The programme of the 26. Pharmacokinetics/Pharmacodynamics Expert Meeting
|
Meeting Location: |
||
| Berghotel Jägerhof, Jägerhof 1, 88316 Isny/Allgäu | ||
|
|
||
| 17:00–19:00 | Arrival Berghotel Jägerhof |
|
| 19:00 | Dinner | |
|
|
||
| 08:30 | Welcome Alexander Staab on behalf of the Organizing Committee |
|
|
Session 1: |
How do PK/PD principles support new modalities? |
|
| 08:45 | Setting the scene – novel modalities meet PKPD Charlotte Kloft & Antje Walz |
|
| 09:00 | Model-guided optimisation of protein degraders: Translating in vitro data to in vivo target degradation profiles (Download Slides) Andreas Reichel, Bayer |
|
| 09:30 | Discussion | |
| 09:45 | Coffee Break | |
| 10:15 | PKPD in support of antisense oligonucleotide (ASO) development; case study with Tominersen®, an ASO for Huntington's disease Nicolas Frances, Roche |
|
| 10:45 | Discussion | |
| 11:00 | Quantitative Modeling Approaches for CAR-T Cell Therapies Anna Mc Laughlin, Pharmetheus |
|
| 11:30 | Discussion | |
| 11:45 | Master / PhD students: Best presentation award (5 min presentation followed by 5 min discussion each) |
|
| 12:30 | Joint Lunch | |
|
Session 2: |
Beyond traditional models: New approaches with high impact on PK/PD |
|
| 14:00 | PK/PD modeling with real-world data integration and its pivotal role in the approval of Continuous Erythropoietin Receptor Activator (C.E.R.A.) i.v. and s.c. in pediatric patients (Download Slides) Pascal Chanu, Roche, and Samer Mouksassi, Certara |
|
| 14:30 | Discussion | |
| 14:45 | PK parameters derived from phys.-chem properties using AI & ML approaches: selection of brain penetrant molecules for a CNS indication. (Download Slides) Gerhard Hessler, Sanofi |
|
| 15:15 | Discussion | |
| 15:30 | Coffee Break | |
| 16:00 | Organotypic and microphysiological liver models to emulate the kinetics of human drug response (Download Slides) Volker Lauschke, Bosch Institute of Clinical Pharmacology |
|
| 16:30 | Discussion | |
| 16:45 | Hans Günter Schäfer Award and Best Presentation Award Moderated by Alexander Staab |
|
| 17:15 | End of Session | |
| 17:30 | Joint Jogging | |
| 19:30 | Dinner | |
|
|
||
|
Session 3: |
Advancements in classical topics: Recent approaches in pediatrics |
|
| 09:00 | Pediatrics in the Regulatory Framework: An Introduction to Recent Pediatrics Guidelines (Download Slides) Eva Berglund, Certara |
|
| 09:30 | Discussion | |
| 09:40 | Pharmacometrics-enhanced Bayesian borrowing for pediatric extrapolation – The DINAMO® trial (Download Slides) Valerie Nock and Oliver Sailer, Boehringer-Ingelheim |
|
| 10:10 | Discussion | |
| 10:20 | Qualification of NT-proBNP as a predictor of clinical outcomes in pediatric patients with heart failure using RWD (Download Slides) Michaela Meyer, Bayer |
|
| 10:50 | Discussion | |
| 11:00 | Model-informed and statistics-based evidence generation for real-world problems of pediatric patients (Download Slides) Katharina Goetz, University of Saarland, Dietrich Knoerzer, Roche |
|
| 11:30 | Discussion | |
| 11:45 | Closing Remarks Alexander Staab on behalf of the Organizing Committee |
|
| 12:15 | Joint Lunch | |
| 13:00 | End of Meeting | |
